Webster Equity Partners Acquires Lifecore Biomedical for $664M

Webster Equity Partners is set to acquire Lifecore Biomedical, a prominent contract development and manufacturing organization (CDMO) specializing in sterile injectable pharmaceuticals, in a transaction that could reach up to $663.7 million. This strategic move signals a significant investment in the growing pharmaceutical services sector, which has seen robust demand driven by an aging global population and increasing complexity in drug development.

The acquisition structure includes an upfront cash payment of $6.28 per share for all outstanding common shares, representing a substantial premium of nearly 50% over Lifecore's recent trading price. Further bolstering the potential value for Lifecore shareholders are contingent value rights (CVRs). These CVRs offer the possibility of additional payments, up to $160 million in aggregate, tied to specific revenue and EBITDA performance milestones scheduled for 2028, 2029, and 2030. If all targets are met, the total consideration could ascend to approximately $9.67 per share, a remarkable 130% uplift from the pre-announcement share value.

Lifecore Biomedical, headquartered in Chaska, Minnesota, has carved out a niche in the development, filling, and finishing of sterile injectables, including those utilizing syringes, vials, and cartridges. The company also holds expertise in manufacturing high-purity injectable-grade hyaluronic acid, a key component in various medical and cosmetic applications. This specialized capability positions Lifecore as a valuable asset within the pharmaceutical supply chain, particularly as demand for advanced drug delivery systems continues to expand.

The transaction, unanimously approved by Lifecore's Board of Directors and Transaction Committee, is anticipated to conclude by the close of the fourth quarter of 2026, pending customary regulatory and shareholder approvals. This timeline allows for a 30-day "go-shop" period, during which Lifecore may explore alternative acquisition proposals, a common provision designed to ensure maximum value for shareholders. Following the acquisition's completion, Lifecore's common stock is expected to be delisted from Nasdaq, though the company intends to maintain its operational base and brand identity.

Financing for this significant acquisition is secured, with committed debt facilities provided by MidCap Financial Trust, MSD Partners, and Alcon Research. An equity commitment from funds advised by Webster Equity Partners completes the financial backing. This robust funding underscores the confidence of these financial institutions in Lifecore's future prospects and the strategic rationale behind the acquisition.

The deal highlights a broader trend of private equity firms actively pursuing established players in the pharmaceutical services and CDMO space. The sector benefits from strong underlying growth drivers, including the increasing outsourcing of manufacturing by pharmaceutical companies and the rising demand for specialized drug development expertise. Webster Equity Partners' investment in Lifecore is expected to provide the company with the resources and strategic guidance to accelerate its growth trajectory and capitalize on upcoming commercialization opportunities.